Dow erases 380-point gain Tuesday morning as tech-related and health-care shares drag stock market lower [MarketWatch]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: MarketWatch
The U.S. stock market lost ground Tuesday morning, turning negative as the benchmarks were weighed by declines in shares of health-care names and those linked to information technology. The Dow Jones Industrial Average was off up 73 points, or 0.4%, at 24,045, but had been at an intraday high at 24,512, while the S&P 500 index was down 0.5% at 2,865 after hitting an intrasession peak at 2,921. The technology-laden Nasdaq Composite Index was down 1.2% at 8,624, but had been up 8,830 earlier in the short session. Investors' enthusiasm had been bolstered by hope of staggered reopening plans in U.S. states after the country has been shutdown to help stem the outbreak of COVID-19. Shares of health-care companies Johnson & Johnson , UnitedHealth Group Inc. and Merck & Co. were the biggest drags on the broader market and the Dow.
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBCPR Newswire
- Johnson & Johnson (NYSE:JNJ) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (JNJ): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/1/25 - Form 4
- 11/13/25 - Form 13F-HR
- 10/22/25 - Form 10-Q
- JNJ's page on the SEC website